. 2018 May 24;9(4):308–325. doi: 10.1080/19490976.2018.1465157

The human gut microbiota: Metabolism and perspective in obesity

Aline Corado Gomes ^a,^✉, Christian Hoffmann ^b, João Felipe Mota ^a

PMCID: PMC6219651 PMID: 29667480

ABSTRACT

The gut microbiota has been recognized as an important factor in the development of metabolic diseases such as obesity and is considered an endocrine organ involved in the maintenance of energy homeostasis and host immunity. Dysbiosis can change the functioning of the intestinal barrier and the gut-associated lymphoid tissues (GALT) by allowing the passage of structural components of bacteria, such as lipopolysaccharides (LPS), which activate inflammatory pathways that may contribute to the development of insulin resistance. Furthermore, intestinal dysbiosis can alter the production of gastrointestinal peptides related to satiety, resulting in an increased food intake. In obese people, this dysbiosis seems be related to increases of the phylum Firmicutes, the genus Clostridium, and the species Eubacterium rectale, Clostridium coccoides, Lactobacillus reuteri, Akkermansia muciniphila, Clostridium histolyticum, and Staphylococcus aureus.

KEYWORDS: gut, gut microbiota, immune system, metabolism, obesity

Introduction

The gut microbiota has recently been recognized as an important factor for the development of metabolic diseases and is considered an endocrine organ involved in the maintenance of energy homeostasis and host immunity.¹ Changes in the composition of the gut microbiota due to environmental factors may result in a change in the relationship between the bacteria and the host. This change can result in a low-grade chronic inflammatory process and in metabolic disorders such as those present in obesity.²

The human gut microbiota consists of up to 100 trillion microbes that exist in a largely symbiotic relationship with their human hosts, carrying at least 150 times more genes (the microbiome) than the human genome.³ Based on 16S rRNA-targeted molecular analyses, most bacteria detected in fecal samples from healthy human volunteers belong to two phyla, Bacteroidetes and Firmicutes. The gram-negative Bacteroidetes phylum includes the genera Bacteroides, Prevotella, Parabacteroides, and Alistipes, while the gram-positive Firmicutes includes species such as Faecalibacterium prausnitzii, Eubacterium rectale, and Eubacterium hallii,⁴ as well as many other low abundance species.

The metabolism of some bacteria can facilitate the extraction of calories from the diet, increase fat deposition in adipose tissue, exacerbate hepatic inflammatory processes, and provide energy and nutrients for microbial growth and proliferation.⁵^,⁶ Several microbial genes involved in human metabolism are enriched or depleted in the guts of obese humans.⁷ Obese people tend to have a higher proportion of genes which encode membrane transport functions⁸ and are involved in butyrate production,⁹ whereas the genes related to cofactor, vitamin, and nucleotide metabolism or transcription are more frequently depleted.⁸

Considering this influence of the gut microbiome on the onset and progression of obesity as well as its consequences, knowledge about the gut microbiota could contribute to the development of adjuvant treatments that can beneficially modulate obesity. Some studies have already evaluated the gut microbiota composition in obese individuals; however, the characterization of this microbiota is still not well established, and some results are discordant. Here, we present a review of the physiology and composition of the human gut microbiota with a focus on obese individuals. We divided our review into two topics: the physiology of the gut microbiota and the composition of this microbiota in obese patients.

Methods

In order to discuss gut microbiota composition of obese individuals, we undertook a systematized literature search that included observational studies (cross-sectional, cohort, or case-control) and experimental studies. The following exclusion criteria were used to reduce possible relationships observed due to other comorbidities: diabetes, intestinal diseases, cancer, experimental studies, and studies that supplemented gut microbiota modulators. The literature search was performed in the MEDLINE and Scopus databases, and the references of studies obtained were scanned for other relevant articles that may not have been detected by the primary search. Only studies published in English in the last 10 years were considered for review. The following Medical Subject Headings (MeSH) search strategy was used: (obesity[Title/Abstract] AND full text[sb] AND “last 10 years”[PDat]) AND (gut microbiota composition[Title/Abstract]) AND (full text[sb] AND “last 10 years”[PDat] AND (Humans[Mesh])).

Methodological quality was assessed using the STROBE recommendations (Strengthening the Reporting of Observational Studies in Epidemiology Statement) with separate checklists for conference case-control studies, cohort studies, and cross-sectional studies, and CONSORT recommendations (Consolidated Standards of Reporting Trials) using a checklist of items for reporting trials of nonpharmacological treatments. The final system was a combination of STROBE and CONSORT.

We also conducted a narrative review about the subject in the following topics: function of the gut microbiota on the development of lymphoid structures, function of the gut microbiota on the immune system, function of the gut microbiota on nutrient and lipid metabolism, function of the gut microbiota on the hormones involved in food intake, and gut microbiota and obesity: future perspectives. There were no restrictions placed on the year of publication in this section.

Physiology of the gut microbiota

The gut microbiota harbors incredibly large microbial and genetic diversity, with distinct species associated with specific parts of the gastrointestinal tract. The stomach contains about 10¹ microbial cells per gram of content. The duodenum contains about 10³ cells; the jejunum,10⁴ cells; the ileum, 10⁷ cells; and the colon, 10¹² microbial cells per gram of contents.¹⁰ Therefore, the quantity of bacteria increases from the proximal to the distal portions of the gastrointestinal tract. Notably, the large intestine contains more than 70% of all microorganisms in the body, which are usually associated with the health/disease of the host.¹¹ In addition, the diversity of bacteria is higher in the lumen and lower in the mucus layer.¹²

High numbers of bacteria in the gastrointestinal tract result in biochemical diversity and metabolic activity that interacts with host physiology. These microorganisms can facilitate the metabolism of non-digestible polysaccharides, produce essential vitamins, and they also play an important role in the development and differentiation of the intestinal epithelium and the host immune system.¹³

Most species are anaerobic and belong to two phyla: Firmicutes and Bacteroidetes. Bacteria belonging to the phyla Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, and Cyanobacteria are widely spread in human populations, but at much lesser abundance.¹⁴ Although controversial, the ratio of Firmicutes-to-Bacteroidetes has been investigated and associated with the predisposition of diseases.¹⁵ Moreover, the low abundance of phylum Proteobacteria associated with a high amount of the genera Bacteroides, Prevotella, and Ruminococcus has been associated with a healthy intestinal microbiota.¹⁶ The maintenance of a healthy gut microbiota is important for a symbiosis relationship with the host.

Function of the gut microbiota on the development of lymphoid structures

The lymphatic system consists of a set of lymphatic vessels that interconnect primary to secondary lymphoid organs. Recirculation of the interstitial fluid and the transport of lymphocytes and antigen-presenting cells occur through this system. These immune cells are produced in the primary lymphoid tissues (thymus and bone marrow) and are activated in the secondary lymphoid tissues (spleen, lymph nodes, and mucosa-associated lymphoid tissue (MALT)).¹⁷

Among the MALT, the gut-associated lymphoid tissues (GALT) are non-encapsulated tissues composed of Peyer's patches, isolated lymphoid follicles, and crypt plaques¹⁸ that begin to form during embryogenesis, when the environment is sterile. At this stage, the mesenchymal cells are induced by retinoic acid to produce the chemokine (C-X-C motif) ligand 13 (CXCL13) that attracts the human lymphoid tissue inducer (LTi) cells. Mature LTi cells induce differentiation of stromal cells and attract immune cells, which form the GALT.¹⁷

The maturation of this tissue depends on microbial colonization after birth.¹⁹ The stromal and epithelial cells recognize bacterial peptidoglycan through the signaling pattern recognition receptors (PRR), nucleotide-binding oligomerization domain-containing protein 1 (NOD1), and Toll-like receptors (TLRs). Activation of these receptors by the gut microbiota increases the expression of CC chemokine ligand 20 (CCL20) and β defensin 3 ligand (HBD3), which activate the formation of isolated lymphoid follicles from the binding of chemokine receptor 6 (CCR6) in LTi.²⁰ Changes in the microbial composition, which happens in obese individuals, can further disrupt the integrity of the intestinal barrier promoted by GALT, leading to pathological bacterial translocation and the initiation of an inflammatory response.²¹

Function of the gut microbiota on the immune system

Besides acting on the maturation of GALT, the commensal bacteria also prevent the intestinal colonization by pathogens. The gut microbiota improves the function of the epithelial barrier, while its absence decreases the production of antimicrobial peptides by Paneth cells. This event causes intestinal barrier dysfunction and increases bacterial translocation.²² Furthermore, bacteria-induced myeloid differentiation factor 88 (MyD88) signaling in the intestine increases epithelial cell IgA secretion. In addition, bacterial flagellin activates Toll-like receptors 5 (TLR5) from dendritic cells, and promotes the differentiation of B lymphocytes into IgA-producing cells²³ IgA binds to the microbial antigens, neutralizes the activity of the pathogens, and prevents infection.²⁴

Commensal bacteria modulate the innate immune response of the host by stimulating the production of homeostatic levels of pro-IL-1β by resident macrophages so that the response of these cells to an enteric infection occurs more rapidly.²⁵ The protective role of IL-1β in intestinal immunity is mediated by the induction of expression of endothelial adhesion molecules, which contribute to neutrophil recruitment and destruction of pathogens in the gut.²⁶

Besides that, modulation of natural killer (NK) T cells is also performed by commensal bacteria. NK T cells are a subset of T cells that simultaneously express both T cell receptor (TCR) and NK cell receptors. These cells promote inflammation from the secretion of cytokines IL-2, IL-4, IL-13, IL-17A, IL-21, tumor necrosis factor (TNF), and interferon-γ (IFN- γ).²⁷ Maintenance of homeostasis of these cells prevents an exaggerated inflammatory reaction.²⁸

Also, an increase in inflammation has been associated with an increase in obesity-associated diseases, such as cardiovascular disease²⁹ and type 2 diabetes.³⁰ Intestinal dysbiosis (changes in gut microbiota composition) can be related to the trigger of a persistent low-grade inflammatory response in obese individuals. Lipopolysaccharides (LPS) contain lipid A, which can cross the intestinal mucosa through tight junctions or with the aid of chylomicrons.³¹^,³² Lipoproteins are responsible for the absorption and transport of dietary triglycerides, and could thus initiate an inflammatory process that could result in the insulin resistance often observed in obesity.³¹^,³² In the systemic circulation, LPS causes an innate immune response in liver and adipose tissue. This occurs from the binding of LPS to the LPS binding protein (LBP), which activates the CD14 receptor.³² This complex binds to Toll-like 4 receptors (TLR4) on macrophages and adipose tissue, resulting in a signaling pathway that activates the expression of genes encoding pro-inflammatory proteins, such as factor nuclear kappa B (NF-κB) and activator protein 1 (AP-1).³²^,³³

LPS concentrations are low in healthy people, but may reach high concentrations in obese individuals and cause metabolic endotoxemia.³¹ This metabolic endotoxemia is related to the development of insulin resistance.³⁴ The molecular mechanisms that relate the activation of TLR4 by LPS with insulin resistance still need to be clarified, but evidence indicates that it involves alteration of insulin receptor signaling by the presence of inflammatory cytokines.³⁵

Function of the gut microbiota on nutrient metabolism and lipid metabolism

The gut microbiota derives its nutrients from the fermentation of carbohydrates ingested by the host. Bacteroides, Roseburia, Bifidobacterium, Fecalibacterium, and Enterobacteria are among the bacterial groups that typically ferment undigested carbohydrates and synthesize short chain fatty acids (SCFA)³⁶ such as acetate, butyrate, and propionate. A significant amount of acetate enters the systemic circulation and reaches the peripheral tissues, while the propionate is mainly used in liver, and the butyrate is used in intestinal epithelium as an energy source.³⁷ The total and relative concentrations of SCFA depend on the fermentation site, the carbohydrate consumed, and the composition of the gut microbiota.³⁸

In addition to synthesizing vitamin K and vitamin B components, several species belonging to the Firmicutes and Actinobacteria phyla are conjugated linoleic acid (CLA) producers.³⁹ CLA is a mixture of positional and geometric isomers of linoleic acid shown by some studies to have anti-obesity properties such as: increase in energy metabolism and expenditure, decrease in adipogenesis, decrease in lipogenesis, and increase in lipolysis and adipocyte apoptosis.³⁹ The biological effects of CLA have been attributed to two possible mechanisms of action: 1) CLA displaces the arachidonic acid from cell membrane phospholipids, which decreases the synthesis of arachidonic acid-derived eicosanoids such as prostaglandins and leukotrienes involved in inflammation,⁴⁰ and 2) CLA mediates activation of transcription factors such as peroxisome proliferator-activated receptors (PPARs), which impact cell processes such as lipid metabolism, apoptosis, and immune function.⁴⁰

Short chain fatty acids

The gut microbiota of obese mice had a higher amount of genes that encode enzymes involved in carbohydrate metabolism and greater capacity to extract energy from the diet and to produce SCFA when compared to non-obese mice.⁴¹ In addition, germ-free mice were resistant to diet-induced obesity.⁴²

SCFAs bind to G protein-coupled receptors (GPCR41 and GPCR43).³⁶ Acetate binds primarily to GPCR43, the propionate binds to both GPCR41 and GPCR43, and the butyrate binds to GPCR41. GPCR41 and GPCR43 receptors are expressed in the intestinal epithelium³⁷ and in adipose tissue.³⁶ The presence of GPCRs in adipose tissue suggests that this tissue is an important target for the metabolites produced by the gut microbiota. One study identified that rats fed a high fat diet had higher GPCR43 expression in adipose tissue and in vitro. SCFA increased the expression of PPARs, an important mediator of adipogenesis.⁴³ SCFAs that are bound to GPCR41 stimulate the expression of leptin in adipocytes and those that bind to GPCR43 appear to stimulate adipogenesis.⁴⁴ Thus, the profile of fatty acids produced may be related to the development of obesity. However, further investigations should be performed to confirm these results in humans.

Lipid metabolism

The endocannabinoid system is expressed in tissues that control energy balance (pancreas, muscle, gut, fat, liver, and hypothalamus) and regulates feeding behavior and metabolism.⁴⁵ This system is composed of bioactive lipids that bind to cannabinoid receptors, which results in cell signaling. The best characterized of these lipids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG),⁴⁶ which activate receptors coupled to G, CB1, and CB2 proteins, thus activating the PPARα, GPR55, and GPR119 receptors.⁴⁷ The modulation of the gut microbiota or the reduction of CB1 activation improves the integrity of the intestinal barrier and reduces metabolic endotoxemia and low-grade inflammation.⁴⁷ Metabolic endotoxemia increased adipocyte hyperplasia and recruitment of macrophages into adipose tissue in a CD14 dependent pathway and increases the production of activin A, which activated the proliferation of adipocyte precursor cells. In addition, the consumption of a high fat diet caused endotoxemia and favored the development of metabolic diseases, suggesting that components of gut bacteria can remodel adipose tissue.⁴⁸ The control of this mechanism can prevent the development of obesity and its comorbidities.⁴⁸

In addition to altering the adiposity process, the microbiota acts at many levels, from lipid processing and absorption to systemic lipid metabolism.⁴⁹^,⁵⁰ This change can be explained by the assimilation of cholesterol by bacterial cells, binding of cholesterol to bacterial cell walls, inhibition of hepatic cholesterol synthesis, redistribution of cholesterol from the plasma to the liver through the action of SCFA and/or deconjugation of bile acids by hydrolysis.⁵¹

Evidence also suggests a link between dysbiosis and pathological changes in the metabolism of deconjugated bile acids in obese patients.⁵² Bacterial bile salt hydrolase (BSH) enzymes in the gut cleave the amino acid side chain of glyco- or tauro-conjugated bile acids to generate unconjugated bile acids (cholic and chenodeoxycholic acids), which are then amenable to further bacterial modification to yield secondary bile acids (deoxycholic and lithocholic acid).⁵³ Secondary bile acids binded to cellular receptors, such as G protein-coupled receptor TGR5,⁵⁴ and reduced macrophage inflammation and lipoprotein uptake resulting in less atherosclerotic plaque formation, which decreased the development of atherosclerosis.⁵⁵

Function of the gut microbiota on the hormones involved in food intake

The gut microbiota has been implicated in the control of food intake and satiety through gut peptide signaling, where bacterial products activate enteroendocrine cells by modulating enterocyte-produced paracrine signaling molecules.⁵⁶ Gut microbiota may increase production of certain SCFA, which have been shown to be associated with an increase in peptide YY (PYY),⁵⁷ ghrelin, insulin, and glucagon-like peptide-1 (GLP-1) production.⁵⁸

Ghrelin was negatively correlated with Bifidobacterium, Lactobacillus, and B. coccoides/Eubacterium rectale, and positively correlated with Bacteroides and Prevotella.⁵⁹ Ingestion of oligofructose, a prebiotic that promotes the growth of Bifidobacterium and Lactobacillus, decreased the secretion of ghrelin in obese human.⁶⁰

GLP-1 also is modulated by the gut microbiota and is responsible for controlling food intake and insulin secretion. The concentration of this hormone was lower in obese individuals compared to eutrophic individuals.⁶¹^,⁶² Butyrate produced by intestinal bacteria was present in smaller amounts in obese individuals⁶³ and regulated energetic homeostasis by stimulating adipocytes to produce leptin and by inducing GLP-1 secretion by L cells.⁶⁴ At least in mice, modulation of the gut microbiota by probiotics increased the production of butyrate by commensal bacteria, inducing the production of GLP-1 by intestinal L cells and thus reducing adiposity.⁶⁵

In addition, the gut microbiota may favor the formation of specific bile acids that activate the TGR5 receptors. Intestinal bacteria dehydrate chenodeoxycholic acid⁶⁶ and produce lithocholic acid, which binds to TGR5⁶⁷ and increases energy expenditure in brown adipose tissue and GLP-1 secretion by activation in the intestinal L cells,⁵⁴ thus preventing obesity and insulin resistance.⁶⁸

The insulin concentrations also appear to be altered in accordance with the gut microbiota.⁶⁹ Gut microbiota transplantation from lean subjects to patients with metabolic syndrome increased insulin sensitivity.⁷⁰ This effect is probably related to the reduction of chronic low-grade inflammation, resulting from LPS translocation and, consequently, to greater activation of the insulin signaling cascade.⁷¹ Like GLP-1, PYY is also produced by intestinal L cells in the form of PYY1–36 and PYY3–36, the latter being present in higher concentrations in the postprandial period, causing a sensation of satiety.⁷² Obese individuals produced less PYY3–36, and no resistance to the hormone was observed. Batterham et al.⁷³ found a 30% reduction in food intake 90 minutes after the infusion of PYY3–36 in obese individuals, a value similar to eutrophic patients. The modulation of the gut microbiota with prebiotic (oligofructose) of healthy subjects resulted in increased bacterial fermentation, glucose tolerance, and reduced appetite from increased concentrations of GLP-1 and PYY,⁷⁴ probably due to a mechanism associated with the production of propionate by intestinal bacteria.⁷⁵ Therefore, the gut microbiota is also related to the development of obesity, due to the possible capacity to alter the food intake.

The human gut microbiota composition in obesity

Phyla changes after weight loss

A higher Firmicutes-to-Bacteroidetes ratio related to obesity was observed in obese children when compared to normal weight children,⁷⁶^,⁷⁷ in overweight/obese women with metabolic syndrome when compared with overweight/obese women with non-metabolic syndrome,⁷⁸ and in Japanese overweight individuals when compared with non-overweight individuals.⁷⁹ Furthermore, the Firmicutes phylum has been shown to be negatively correlated with the resting energy expenditure (REE) as well as positively correlated with fat mass percentage.⁸⁰ A cross-over clinical trial observed that a 20% increase in the Firmicutes phylum abundance was associated with an increase of 150 kcal in energy harvest.⁸¹ Finally, one study reported a decrease in the Firmicutes-to-Bacteroidetes ratio after weight loss by obese individuals (Table 1).¹⁵

Table 1.

Main results of studies that evaluated the gut microbiota composition in obesity.

Ref	Subjects’ characteristics	Age	Design	Objective	Methods of detection	Results	Quality
84	Overweight pregnant women (n = 18)	Overweight: 30.0 years (26.4–34.0)	Case-control	To characterize the gut microbiota in women according to their body mass index (BMI) and the effect of weight gain over pregnancy on the composition of microbiota before delivery	FISH and qPCR	Overweight: ↑ Bacteroides, Staphylococcus aureus and Clostridium	B
	Normal weight (n = 36)	Normal weight: 30.5 years (26.6–33.6)				Bacteroides: positive correlation with weight and BMI before pregnancy and weight gain over pregnancy
						*Bifidobacterium*: ↑ in women with lower weight gain over pregnancy
91	Overweight and obese children (n = 25)	7 years	Cross-sectional	To establish whether early gut microbiota composition can guide weight development throughout early childhood	FISH and qPCR	Overweight: ↑ Staphylococcus aureus	B
91	Normal weight (n = 24)					Normal weight: ↑ Bifidobacterium numbers
85	Mothers and their infants.	Pre-pregnancy overweight: 28.55 years (26.2–34.12)	Cross-sectional	To analyze the fecal microbiota composition of infants with overweight and normal weight mothers and to assess the relationship of weight and excessive weight gain of mothers during pregnancy on the microbiota of infants	FISH and qPCR	Infants of overweight mothers: ↓Bacteroides-Prevotella; ↑Clostridium histolyticum; ↑Staphylococcus aureus; ↑Akkermansia muciniphila; ↑Akkermansia	B
	Pre-pregnancy body mass index >25 (n = 16) or normal weight (n = 26)	Normal weight: 30.04 years (26.43–33.70)				Infants of normal weight mothers: ↑Bifidobacterium; ↓Bifidobacterium adolescentis
		Infants: 1–6 months				Infants of mothers with excessive weight gains: ↓Bacteroides-Prevotella; ↑Clostridium histolyticum; ↓Bifidobacterium; ↑Staphylococcus aureus
88	N = 30 morbidly obese women enrolled in a bariatric surgery program	—	Clinical trial	To examine the impact of Roux-en-Y gastric bypass (RYGB) on modifications of gut microbiota and its potential associations with changes in gene expression in white adipose tissue	Multiplex pyrosequencing	After RYGB: ↑richness of gut microbiota; ↓Firmicutes (Lactobacillus, Dorea, and Blautia); ↓Bifidobacterium; ↑Bacteroidetes (Bacteroides and Alistipes); ↑Escherichia	B
77	Overweight and obese children and adolescents (n = 26)	Overweight and obese: 11.64 ± 2.43 years	Cross-sectional	To investigate and compare the gut microbiota composition in obese and lean children	qPCR and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry	Obese: ↑Firmicutes-to-Bacteroidetes ratio; ↑Lactobacillus spp; ↓Bacteroides vulgatus	B
	Normal weight (n = 27)	Normal weight: 10.70 ± 3.12 years				Lactobacillus spp.: positively associated with plasma hs-CRP
						Staphylococcus spp.: positively associated with energy intake
	N = 12 obese people	(21–65)	Clinical trial	To investigate the relationship between gut microbial ecology and body fat in humans	qPCR	92.6% of gut microbiota (obese): Bacteroidetes and Firmicutes	B
15	Fat-restricted low-calorie diet (FAT-R) (n = 6)					Before diet therapy: ↓Bacteroidetes; ↑Firmicutes
	Carbohydrate-restricted low-calorie diet (CARB-R) (n = 6)					After diet therapy: ↑Bacteroidetes; ↓Firmicutes
						↑Bacteroidetes: positively correlated with percentage loss of body weight
80	Obese (n = 50)	Obese: 51.9 years (48.1–55.7)	Cross-sectional	To assess the composition of gut microbiota and its association with resting energy expenditure (REE) in obese and normal weight subjects	Semi-quantitative analysis of gut microbiota composition in aerobic and anaerobic conditions	Bacteroides-to-Firmicutes rate was similar in both study groups	B
	Normal weight (n = 30)	Normal weight: 42.6 years (38.1–47.1)				Positive correlation between:
						REE (kcal/day) and total bacterial count
						REE (kcal/m²/h) and total bacterial count
						Firmicutes count and percentage of fat mass
						Negative correlation between:
						REE (kcal/day) and percentage of Firmicutes
						REE (kcal/m²/h) and percentage of Firmicutes
89	Obese women who underwent laparoscopic sleeve gastrectomy (LSG) (n = 5) or dietary weight loss regimen (n = 5)	48 ± 3 years	Longitudinal pilot clinical trial	To investigate functional weight loss mechanisms with regard to gut microbial changes and energy harvest induced by LSG and a very lowcalorie diet	SOLiD long-mate-paired shotgun sequencing	LSG: ↑Bacteroidetes and ↓Firmicutes (Clostridium, Eubacterium, Faecalibacterium, Dorea, and Coprococcus); ↑Butyrivibrio fibrisolvens; ↑Clostridium saccharolyticum; ↑Eubacterium; ↑Blautia hydrogenotrophica; Bacteroidetes showed a negative correlation with body weight; Firmicutes were positively correlated with body weight	B
89						Dietary intervention: ↓Bacteroidetes; body weight correlated significantly positively with Bacteroidetes and negatively with Firmicutes	B
103	African Americans (n = 42)	African Americans: 51.2 years	Cross-sectional	To investigate if differences in dietary habits between the two groups are associated with cytotoxicity/ genotoxicity of fecal water and with fecal microbiota composition	FISH and qPCR	↑ Calories from fat: ↓Clostridium;	B
	Caucasian Americans (n = 40)	Caucasian Americans: 52.3 years		To evaluate associations between obesity and microbiota composition, 14 lean (BMI <25) and 14 randomly chosen obese subjects (BMI >30) were selected		↑ Dietary fiber: ↑lactic acid bacteria;	B
						BMI was not associated with proportions of Bacteroides or Firmicutes
83	Obese (n = 68)	Obese: 50.5 ± 14.4 years	Cross-sectional	To test whether Lactobacillus or Bifidobacterium species found in the human gut are associated with obesity or lean status	qPCR	Obese: ↑Lactobacillus reuteri; ↑Lactobacillus; E. coli	A
	Control (n = 47)	Control: 42.6 ± 17.5 years				Control: ↑Lactobacillus paracasei; Lactobacillus plantarum;
						Methanobrevibacter smithii, Bifidobacterium animalis
						*B. animalis*: was associated with normal weight
						*L. reuteri*: was associated with obesity
78	Overweight/obese women in metabolic disorder group (MDG, n = 27) or in non-metabolic disorder group (NMDG, n = 47) or normal weight women group (NWG, n = 11)	MDG: 42 ± 8 years	Cross-sectional	To investigate whether overweight/obese women in MDG differ in their gut microbiota composition from overweight/obese women in NMDG and NWG	FISH	MDG: ↑E.rectale-C.coccoides, ↑gram-negative, ↑Erec-to-Bacto ratio, ↑Firmicutes/Bacteroidetes ratio	A
		NMDG: 39 ± 9 years				E. rectale-C. coccoides group: positive correlation with ↑body weight, BMI, FM, FM%, visceral fat area, and serum triglycerides; negative correlation with HDL concentrations
		NWG: 31 ± 14 years				Bacteroides: inverse correlation with body weight, BMI, FM, FM%, and insulin concentration; positive correlation with HDL
92	Obese (n = 33)	43 ± 13.85 years	Clinical trial	To identify bacteria affecting host metabolism in obesity during weight loss and to correlate them with changes in body composition	qPCR	After weight reduction: ↑ total bacterial abundance, Lactobacillus, Akkermansia; ↓ ratio of Firmicutes/Bacteroidetes, Clostridium;	A
						Differences in lactobacilli abundance correlated with differences in weight percentage
90	Pregnant women (24 weeks of pregnancy)	Overweight: 29 years (28.0–33.5)	Cross-sectional	To establish possible relationships between gut microbiota, body weight, weight gain, and biochemical parameters in pregnant women	qPCR	Obese women: ↑Enterobacteriaceae; ↑Escherichia coli; ↑Staphylococcus	B
	Overweight (n = 16)	Normal weight: 31 years (27.7–34.2)				Normal weight: ↑Bifidobacterium; ↑ratio of Bifidobacterium to C. coccoides group
	Normal weight (n = 34)					Excessive weight gain: ↑ Escherichia coli; ↑C. leptum; ↑Staphylococcus ↓Akkermansia muciniphila; ↓Bifidobacterium
104	Overweight adolescents randomized in low weight loss group (n = 13) or high weight loss group (n = 23) Intervention based on an energy-restricted diet and regular physical activity	14.5 years (13.0–15.0)	Clinical trial	To determine the influence of an obesity treatment program on the gut microbiota and body weight of overweight adolescents	qPCR	Both: ↑Bacteroides fragilis; ↑Lactobacillus; ↓Clostridium coccoides; ↓Bifidobacterium longum; ↓Bifidobacterium adolescentis	A
						**Bacteroides fragilis and Clostridium leptum**: positively correlated with higher weight loss
						**Escherichia coli, Clostridium coccoides, Lactobacillus and Bifidobacterium**: negatively correlated with higher weight loss
						**B. breve and B. bifidum**: correlated with lower weight loss
82	Obese (n = 20)	Obese: 17–72 years	Cross-sectional	To assess the relative abundance of Lactobacillus, Methanobrevibacter smithii, Bacteroidetes, and Firmicutes divisions in the microbiota of obese, lean, and patients with anorexia nervosa	qPCR	Obese: ↓Bacteroidetes; ↑Lactobacillus	B
	Anorexia nervosa (n = 9)	Anorexia: 19–36 years				The anorexic bacterial profile is similar to the lean control group
	Normal weight (n = 20)	Normal weight: 13 –68 years
86	15 obese male subjects and 14 non-obese subjects	—	Cross-over clinical trial	To examine the relationships between BMI, weight loss, and the major bacterial groups detected in fecal samples	FISH	Bacteroides: No difference between obese and non-obese individuals	B
	4 weeks: high-protein low carbohydrate					No relationship between changes in the percentage of Bacteroides and weight lost
	4 weeks: high-protein moderate carbohydrate					After diet: ↓Roseburia+Eubacterium rectale; ↓Bifidobacteria; no change in the percentage of Firmicutes; no change in the percentage of Bacteroidetes
87	Normal weight (n = 3)	Normal weight: 36.7 ± 4.0 years	Cross-sectional	To identify specific microbial lineages that may play important roles in the development of obesity and also to determine whether the presence or abundance of these microorganisms changes after successful post-gastric bypass surgery	qPCR	Obese: ↑Prevotellaceae; ↑Archaea; ↑Firmicutes	B
	Obese (n = 3)	Obese: 35.7 ± 4.2 years				Post-gastric bypass: ↓Firmicutes, ↑Gammaproteobacteria
	Post-gastric bypass (n = 3)	Post-gastric bypass: 43.3 ± 8.1 years
93	Normal weight (n = 13)	—	Cross-sectional analyses: before (M0), 3 months (M3), and 6 months (M6) after Roux-en-Y gastric bypass	To analyze the impact of RYGB on the modifications of gut microbiota and to examine links with adaptations associated with this procedure	qPCR	Obese M0: ↓ Bacteroides/Prevotella; ↓F. prausnitzii	B
	Obese (n = 30)					Obese M3: ↑Bacteroides/Prevotella; ↑Escherichia coli; ↑ Faecalibacterium prausnitzii; ↓Bifidobacterium; ↓Lactobacillus/Leuconostoc/Pediococcus groups;
						F. prausnitzii: negatively correlated with inflammatory markers
						Bacteroides/Prevotella and E. coli: correlated negatively with body weight, BMI, body fat mass, and serum leptin concentrations
						Bacteroides/Prevotella: correlated negatively with calorie intake
81	Normal weight (n = 12)	Normal weight: 32.8 ± 9.2 years	Cross-over clinical trial	To test how gut bacterial community structure is affected by altering the nutrient load in lean and obese individuals and whether their microbiota is correlated with the efficiency of dietary energy harvest	Multiplex pyrosequencing	97%: Firmicutes + Bacteroidetes	A
	Obese (n = 9)	Obese: 35.8 ± 10.6 years				↑20% in Firmicutes and ↓ Bacteroidetes: energy harvest of ≈150 kcal
83	Obese (n = 134)	Obese: 51.8 ± 14.7 years	Cross-sectional	To analyze the fecal concentrations of Bacteroidetes, Firmicutes, Methanobrevibacter smithii, the genus Lactobacillus, and five other Lactobacillus species previously linked with lean or obese populations	PCR	Obese: ↑Lactobacillus; ↑Lactobacillus reuteri; ↓Bacteroidetes; ↓M. smithii; ↓Bifidobacterium animalis; ↓E. coli	A
	Overweight (n = 38)	Overweight: 54.1 ± 17.8 years				Overweight: ↑L. reuteri
	Normal weight (n = 76)	Normal weight: 49.5 ± 18.6 years				Positive correlation between: L. reuteri and BMI
	Anorexic patients (n = 15)	Anorexic patients: 27.3 ± 10.8				Negative correlation between: M. smithii and BMI; E. coli and BMI
79	Overweight (n = 33)	Overweight: 54.4 ± 8.2 years	Cross-sectional	To examine the human gut microbiota composition in a Japanese population	Next generation sequencing	Overweight:	B
	Normal overweight (n = 23)	Normal weight: 45.6 ± 9.6 years				↓Bacteroidetes; ↑Firmicutes-to-Bacteroidetes ratio; ↑Microbial diversity; ↑Blautia hydrogenotorophica; ↑Coprococcus catus; ↑Eubacterium ventriosum; ↑Ruminococcus bromii; ↑Ruminococcus obeum
						Normal weight: ↑Bacteroides faecichinchillae; ↑Bacteroides thetaiotaomicron; ↑Blautia wexlerae; ↑Clostridium bolteae; ↑Flavonifractor plautii
76	Obese (n = 42)	6–16 years	Cross-sectional	To characterize the composition of the gut microbiota in obese and normal weight individuals	PCR	Obese: ↓Bacteroidetes; ↑Firmicutes; ↑Firmicutes-to-Bacteroidetes ratio	B
	Normal weight (n = 36)

Open in a new tab

LSG: laparoscopic sleeve gastrectomy; qPCR: quantitative polymerase chain reaction; FISH: fluorescent in situ hybridization; FM: fat mass; HDL: high density lipoprotein.

Obese individuals seem to have fewer Bacteroidetes counts than normal weight individuals.⁷⁹^,⁸²^,⁸³ On the other hand, two studies associated the Bacteroidetes phylum with weight gain in pregnant women.⁸⁴^,⁸⁵ A cross-over study with 29 subjects did not find differences in the proportion of Bacteroidetes between obese and non-obese individuals (Table 1).⁸⁶

A decrease of Firmicutes was observed after Roux-en-Y gastric bypass (RYGB)⁸⁷^,⁸⁸ and after laparoscopic sleeve gastrectomy (LSG).⁸⁹ In contrast, Bacteroidetes counts increased after RYGB and LSG⁸⁸^,⁸⁹ but after a very low-calorie diet.⁸⁹ This phylum decreased with a concomitant increase in the Firmicutes phylum. A decrease in the Firmicutes-to-Bacteroidetes ratio after diet therapy also was observed, and the Bacteroidetes proportion was positively correlated with a percentage of loss of body fat (Table 1).¹⁵

Obesity related genus changes

The genera Staphylococcus⁷⁷^,⁸⁴^,⁸⁵^,⁹⁰^,⁹¹ and Clostridium⁸⁴^,⁸⁵^,⁸⁹^,⁹² have been shown to be positively associated with obesity. A decrease in the genus Faecalibacterium was reported after LSG,⁸⁹ while the same genus increased after RYGB.⁹³ All these genera belong to the Firmicutes phylum (Table 1). The Firmicutes phylum contains many butyrate producing species, and an increase in butyrate and acetate synthesis may contribute to an increase in energy harvest in obese people.¹⁵^,⁹⁴ Furthermore, acetate can be absorbed and used as a substrate for lipogenesis and gluconeogenesis in the liver.⁴⁹

The genus Bacteroides, which belongs to the phylum Bacteroidetes, was shown to have an inverse relationship with obesity in overweight/obese women with metabolic disorder⁷⁸ after RYGB⁸⁸^,⁹³ and LSG (Table 1).⁸⁹ Bifidobacterium, which belongs to the phylum Actinobacteria, was also shown to have an inverse relationship with obesity in pregnant women,⁸⁴^,⁹⁰ children,⁹¹ and infants of normal weight mothers⁸⁵; however, this genus was decreased in individuals subjected to RYGB.⁸⁸^,⁹³ Bifidobacterium species have been shown to deconjugate bile acids, which may decrease fat absorption.⁹⁵ In contrast, strains of the same species can have contradictory effects, as it has been shown that different Bifidobacterium strains might increase (strain M13–4) or decrease body weight (strain L66–5).⁹⁶

Methane-producing archaea (methanogens) have been shown to affect caloric harvest by increasing the capacity of polysaccharide-eating bacteria to digest polyfructose containing glycans, which leads to increased weight gain in mice.⁴¹ A study demonstrated that humans with methane detectable via a breath test have a significantly higher body mass index (BMI) than methane-negative controls (Table 1). This implies a higher amount of M. smithii in obese individuals, which was not observed in studies assessing gut archaeal populations.⁹⁷

Gut microbiota and obesity: future perspectives

Although several links have been reported between the gut microbiome and obesity (Table 2), the mechanisms are not yet understood that explain how and when the microbiome affects the obese state. Most studies investigating the relationships between obesity and the gut microbiome use very small sample sizes and use a variety of analytical methods to infer the intestinal microbial composition. Such factors are likely responsible for the considerable heterogeneity observed in the results. For instance, different DNA extraction kits have an impact on the assessment of the human gut microbiota, making it difficult to compare data across studies.⁹⁸

Table 2.

Genus and species of bacteria and its relation to obesity.

Species	Genus	Phylum	Characteristics	In obese individuals	Effect associated with obesity
—–	Bacteroides	Bacteroidetes	gram -; anaerobic; non-spore-forming	↓ Except in pregnant women	↓absorption of dietary fat¹⁰⁵; GALT development¹⁰⁶
Bacteroides vulgatus	Bacteroides	Actinobacteria	gram -; anaerobic; non-spore-forming	↓	Part of the core gut microbiota in healthy humans¹⁴
Bacteroides fragilis	Bacteroides	Bacteroidetes	gram -; anaerobic; non-spore-forming	↓	↑IL-10 production¹⁰⁷
Staphylococcus aureus	Staphylococcus	Firmicutes	gram +; facultative anaerobe; non-spore-forming	↑	Trigger of low-grade inflammation⁹¹
——	Clostridium	Firmicutes	gram +; anaerobic; spore-forming	↑	↑Energy storage; ↑low-grade inflammation⁸⁵
Clostridium histolyticum	Clostridium	Firmicutes	gram +; facultative anaerobe; produces endospores	↑	Produces acetate, that ↑lipid synthesis¹⁰⁸
					Produces cytotoxic proteases:¹⁰⁹
Akkermansia muciniphila	Akkermansia	Verrucomicrobia	gram -; anaerobic; non-spore-forming; mucin-degrading bacterium	↑ Except in pregnant women	↑Degradation of intestinal mucin; ↑pro-inflammatory activity⁸⁵
Escherichia coli	Escherichia	Proteobacteria	gram -; facultative anaerobe; non-spore-forming	Disputed	The absence of E. coli was an independent predictor of weight gain⁸³; ↑harvest energy⁸⁸
L. reuteri	Lactobacillus	Firmicutes	gram +; anaerobic; non-spore-forming	↑	↑Gut's ability to absorb and process nutrients¹¹⁰
L. plantarum	Lactobacillus	Firmicutes	gram +; anaerobic; non-spore-forming	↓	↑Conjugated linoleic acid, which increases energy expenditure and produces an anti-obesity effect¹¹¹
——	Bifidobacterium	Actinobacteria	gram +; anaerobic; non-spore-forming	Disputed	↑Insulin resistance, adiponectin ↓Inflammatory adipokine expressions ↑Conjugated linoleic acid¹¹²
Bifidobacterium adolescentis	Bifidobacterium	Actinobacteria	gram +; anaerobic; non-spore-forming	↓	↓Visceral fat accumulation; ↑Insulin sensitivity¹¹³
Butyrivibrio fibrisolvens	Butyrivibrio	Firmicutes	gram +; anaerobic; non-spore-forming	↓	↑Conjugated linoleic acid¹¹⁴
Faecalibacterium prausnitzii	Faecalibacterium	Firmicutes	gram +; anaerobic; non-spore-forming	↓	Modulates systemic inflammation¹¹⁵
E.rectale-C.coccoides	Eubacterium / Clostridium	Firmicutes	gram +; anaerobic; non-spore-forming/spore-forming	↑	↑Butyrate; ↑Harvest energy from the diet¹¹⁶

Open in a new tab

Probiotics, prebiotics, and antibiotics have been evaluated, and they may become new therapeutic possibilities for the treatment of obesity. Oral supplementation with probiotics seems to reduce the concentrations of low-density lipoproteins (LDL) and total cholesterol; to ameliorate atherogenic indices; to improve glycemic control⁹⁹; to reduce body weight, waist circumference, BMI, and abdominal visceral adipose tissue¹⁰⁰; to improve body composition,¹⁰¹ and to reduce the concentrations of pro-inflammatory markers such as interleukin 6 (IL-6) and TNF-α[¹⁰² Prebiotics also have been shown to contribute to weight loss and improve metabolic parameters including insulin resistance.⁶⁰ Nevertheless, modulations performed with probiotics show results only for specific strains and for the period evaluated, with little data available regarding long-term benefits. In addition, the different ways in which different hosts can react to supplementation make it impossible to carry out generalizations. In the future, the modulation of the gut microbiota may be a way of assisting in the treatment of obesity, but for this idea to become a reality, there is a need to understand the metabolic interactions between the modulated bacteria and the host.

Conclusions

Although there is a large amount of heterogeneity in the data that is available, the following conclusions can be drawn from the literature review: 1) obesity was characterized by the presence of intestinal dysbiosis, marked by the distinct microbiome profile existing between obese and non-obese individuals; 2) the resulting dysbiosis could change the functioning of the intestinal barrier and the GALT, allowing the passage of structural components of bacteria, such as LPS, and activating inflammatory pathways that may contribute to the development of insulin resistance by alteration of insulin receptor signaling by the presence of inflammatory cytokines; 3) intestinal dysbiosis could alter the production of gastrointestinal peptides related to satiety, resulting in an increased food intake and contributing to a self-sustaining cycle; and 4) lipid metabolism could be altered by the changes observed in the gut microbiome, resulting in a stimulus to increase body adiposity (Fig. 1).

Figure 1. — Possible mechanisms that related the obesity and intestinal dysbiosis with the physiological changes that contributed to the maintenance of obesity. GALT: gut-associated lymphoid tissue; IgA: immunoglobulin A; LPS: lipopolysaccharide; NF-κB: nuclear factor kappa B; CLA: conjugated linoleic acids; PPAR: peroxisome proliferator-activated receptor; LPL: lipoprotein lipase; Angptl4: angiopoietin like protein 4; GLP-1: glucagon-like peptide 1; PYY: peptide YY.

Understanding the changes occurring in the gut microbiome of obese individuals and the physiological consequences of these changes is a necessary step in creating modulation strategies that can be used to help treat this condition.

List of Abbreviations

2-AG: 2-arachidonoylglycerol
AEA: anandamide
AP-1: activator protein 1
BMI: body mass index
BSH: bile salt hydrolase
CCL20: CC chemokine ligand 20
CCR6: chemokine receptor 6
CLA: conjugated linoleic acid
C-X-C: chemokine
CXCL13: ligand 13 chemokine
GALT: gut-associated lymphoid tissues
GLP-1: glucagon-like peptide-1
GPCR: G protein-coupled receptors
HBD3: β defensin 3 ligand
IFN- γ: interferon-γ
IL-6: interleukin 6
LBP: LPS binding protein
LDL: low-density lipoproteins
LPS: lipopolysaccharides
LSG: laparoscopic sleeve gastrectomy
LTi: lymphoid tissue inducer
MALT: mucosa-associated lymphoid tissue
MyD88: myeloid differentiation factor 88
NF-κB: factor nuclear kappa B
NK: natural killer
NOD1: nucleotide-binding oligomerization domain-containing protein 1
PRR: pattern recognition receptors
PYY: peptide YY
RYGB: Roux-en-Y gastric bypass
SCFA: short chain fatty acids
TCR: T cell receptor
TLR4: Toll-like 4 receptors
TLR5: Toll-like receptors 5
TLRs: Toll-like receptors
TNF: tumor necrosis factor.

Disclosure of potential conflicts of interest

No potential conflicts of interest were disclosed.

Acknowledgments

Not applicable

Authors' contributions

ACG: drafted the manuscript and performed the design of the study. CH and JFM: drafted and revised the manuscript. All authors read and approved the final manuscript.

References

1.Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28:1221–38. doi: 10.1210/me.2014-1108. PMID:24892638. [DOI] [PMC free article] [PubMed] [Google Scholar]
2.Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, et al.. The gut microbiota and host health: a new clinical frontier. Gut. 2016;65:330–9. doi: 10.1136/gutjnl-2015-309990. PMID:1026338727. [DOI] [PMC free article] [PubMed] [Google Scholar]
3.Ursell L, Haiser HJ, Van Treuren W, Garg N, Reddivari L, Vanamala J, Dorrestein PC, Turnbaugh PJ, Knight R. The intestinal metabolome: an intersection between microbiota and host. Gastroenterol. 2014;146:1470–6. doi: 10.1053/j.gastro.2014.03.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ Microbiol. 2010;12:304–14. doi: 10.1111/j.1462-2920.2009.02066.x. PMID:19807780. [DOI] [PubMed] [Google Scholar]
5.Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host bacterial mutualism in the human intestine. Science. 2005;307:1915–20 doi: 10.1126/science.1104816. PMID:15790844. [DOI] [PubMed] [Google Scholar]
6.Neyrinck AM, Etxeberria U, Taminiau B, Daube G, van Hul M, Everard A, Cani PD, Bindels LB, Delzenne NM. Rhubarb extract prevents hepatic inflammation induced by acute alcohol intake, an effect related to the modulation of the gut microbiota. Mol Nutr Food Res. 2017;61:1500899. doi: 10.1002/mnfr.201500899. PMID:26990039 [DOI] [PubMed] [Google Scholar]
7.Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2009;1:6ra14. doi: 10.1126/scitranslmed.3000322. PMID:20368178. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci USA. 2012;1099:594–9. doi: 10.1073/pnas.1116053109. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Ferrer M, Ruiz A, Lanza F, Haange SB, Oberbach A, Till H, Bargiela R, Campoy C, Segura MT, Richter M, et al.. Microbiota from the distal guts of lean and obese adolescents exhibit partial functional redundancy besides clear differences in community structure. Environ Microbiol. 2013;15:211–26. doi: 10.1111/j.1462-2920.2012.02845.x. PMID:22891823. [DOI] [PubMed] [Google Scholar]
10.Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90:859–904. doi: 10.1152/physrev.00045.2009. PMID:20664075. [DOI] [PubMed] [Google Scholar]
11.Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World J Gastroenterol. 2015;21:8787–803. doi: 10.3748/wjg.v21.i29.8787. PMID:26269668. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J. Gastroenterol. 2005;11:1131–40. doi: 10.3748/wjg.v11.i8.1131. PMID:15754393. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Smith K, McCoy KD, Macpherson AJ. Use of axenic animals in studying the adaptation of mammals to their commensal intestinal microbiota. Semin Immunol. 2007;19:59–69. doi: 10.1016/j.smim.2006.10.002. PMID:17118672. [DOI] [PubMed] [Google Scholar]
14.Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59–65. doi: 10.1038/nature08821. PMID:20203603. [DOI] [PMC free article] [PubMed] [Google Scholar]
15.Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022–3. doi: 10.1038/4441022a. PMID:17183309. [DOI] [PubMed] [Google Scholar]
16.Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterol. 2014;146:1449–58. doi: 10.1053/j.gastro.2014.01.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. Nature Rev Immunol. 2010;10:664–74. doi: 10.1038/nri2832. [DOI] [PubMed] [Google Scholar]
18.Pabst O, Herbrand H, Worbs T, Friedrichsen M, Yan S, Hoffmann MW, Körner H, Bernhardt G, Pabst R, Förster R. Cryptopatches and isolated lymphoid follicles: dynamic lymphoid tissues dispensable for the generation of intraepithelial lymphocytes. Eur J Immunol. 2005;35:98–107. doi: 10.1002/eji.200425432. PMID:15580658. [DOI] [PubMed] [Google Scholar]
19.Renz H, Brandtzaeg P, Hornef M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nature Rev Immunol. 2012;12:9–23. doi: 10.1038/nri3112. [DOI] [PubMed] [Google Scholar]
20.Bouskra D, Brézillon C, Bérard M, Werts C, Varona R, Boneca IG, Eberl G. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008;456:507–10. doi: 10.1038/nature07450. PMID:18987631. [DOI] [PubMed] [Google Scholar]
21.Brandl K, Schnab B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. Expert Rev Gastroenterol Hepatol. 2015;9:1069–76. doi: 10.1586/17474124.2015.1057122. PMID:26088524. [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA. 2008;105:20858–63. doi: 10.1073/pnas.0808723105. PMID:19075245. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Uematsu S, Fujimoto K, Jang MH, Yang BG, Jung YJ, Nishiyama M, Sato S, Tsujimura T, Yamamoto M, Yokota Y, et al.. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nature Immunol. 2008;9:769–76. doi: 10.1038/ni.1622. [DOI] [PubMed] [Google Scholar]
24.Frantz AL, Rogier EW, Weber CR, Shen L, Cohen DA, Fenton LA, Bruno ME, Kaetzel CS. Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides. Mucosal Immunol. 2012;5:501–12. doi: 10.1038/mi.2012.23. PMID:22491177. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, et al.. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–98. doi: 10.1016/j.cell.2009.09.033. PMID:19836068. [DOI] [PMC free article] [PubMed] [Google Scholar]
26.Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nature Rev Immunol. 2013;13:321–35. doi: 10.1038/nri3430. [DOI] [PubMed] [Google Scholar]
27.Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res. 2011;343:43–55. doi: 10.1007/s00441-010-1023-3. PMID:20734065. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, et al.. Microbial exposure during early life has persistent effects on natural killer T cell function. Science. 2012;336:489–93. doi: 10.1126/science.1219328. PMID:22442383. [DOI] [PMC free article] [PubMed] [Google Scholar]
29.Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, et al.. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20. doi: 10.1056/NEJMoa1107477. PMID:23034020. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812–7. doi: 10.2337/diabetes.52.3.812. PMID:12606524. [DOI] [PubMed] [Google Scholar]
31.Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al.. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72. doi: 10.2337/db06-1491. PMID:17456850. [DOI] [PubMed] [Google Scholar]
32.Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber A, Hackam DJ. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176:3070–9. doi: 10.4049/jimmunol.176.5.3070. PMID:16493066. [DOI] [PubMed] [Google Scholar]
33.Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328:228–31. doi: 10.1126/science.1179721. PMID:20203013. [DOI] [PMC free article] [PubMed] [Google Scholar]
34.Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015–25. doi: 10.1172/JCI28898. PMID:17053832. [DOI] [PMC free article] [PubMed] [Google Scholar]
35.Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem. 2000;275:9047–54. doi: 10.1074/jbc.275.12.9047. PMID:10722755. [DOI] [PubMed] [Google Scholar]
36.Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta. 2010;1801:1175–83. doi: 10.1016/j.bbalip.2010.07.007. PMID:20691280. [DOI] [PubMed] [Google Scholar]
37.Lin HV, Frassetto A, Kowalik EJ, Nawrocki AR, Lu MM, Kosinski JR, Hubert JA, Szeto D, Yao X, Forrest G, et al.. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS One. 2012;7:e35240. doi: 10.1371/journal.pone.0035240. PMID:22506074. [DOI] [PMC free article] [PubMed] [Google Scholar]
38.Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104–19. doi: 10.1111/j.1365-2036.2007.03562.x. PMID:17973645. [DOI] [PubMed] [Google Scholar]
39.Kennedy A, Martinez K, Schmidt S, Mandrup S, Lapoint K, McIntosh MK. Antiobesity mechanisms of action of conjugated linoleic acid. J Nutr BioChem. 2010;21:171–9. doi: 10.1016/j.jnutbio.2009.08.003. PMID:19954947. [DOI] [PMC free article] [PubMed] [Google Scholar]
40.Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr. 2002;22:505–31. doi: 10.1146/annurev.nutr.22.021302.121842. PMID:12055356. [DOI] [PubMed] [Google Scholar]
41.Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444:1027–31. doi: 10.1038/nature05414. PMID:17183312. [DOI] [PubMed] [Google Scholar]
42.Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104:979–84. doi: 10.1073/pnas.0605374104. PMID:17210919. [DOI] [PMC free article] [PubMed] [Google Scholar]
43.Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, Gotoh C, Choi KC, Feng DD, Chen C, Lee HG, et al.. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology. 2005;146:5092–9. doi: 10.1210/en.2005-0545. PMID:16123168. [DOI] [PubMed] [Google Scholar]
44.Macfarlane GT, Macfarlane S. Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics. J Clin Gastroenterol. 2011;45:S120–S12. doi: 10.1097/MCG.0b013e31822fecfe. PMID:21992950. [DOI] [PubMed] [Google Scholar]
45.Matias I, MarzoV Di. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27–37. doi: 10.1016/j.tem.2006.11.006. PMID:17141520. [DOI] [PubMed] [Google Scholar]
46.Lambert DM, Muccioli GG. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. Curr Opin Clin Nutr Metab Care. 2007;10:735–44. doi: 10.1097/MCO.0b013e3282f00061. PMID:18089956. [DOI] [PubMed] [Google Scholar]
47.Muccioli GG, Naslain D, Backhed F, Reigstad CS, Lambert DM, Delzenne NM, Cani PD. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol. 2010;6:392. doi: 10.1038/msb.2010.46. PMID:20664638. [DOI] [PMC free article] [PubMed] [Google Scholar]
48.Luche E, Cousin B, Garidou L, Serino M, Waget A, Barreau C, André M, Valet P, Courtney M, Casteilla L, et al.. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. Mol Metabolis. 2013;2:281–91. doi: 10.1016/j.molmet.2013.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
49.Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, Felin J, Perkins R, Borén J, Oresic M, et al.. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res. 2010;51:1101–12. doi: 10.1194/jlr.M002774. PMID:20040631. [DOI] [PMC free article] [PubMed] [Google Scholar]
50.Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–9. doi: 10.1038/nature11552. PMID:22972297. [DOI] [PubMed] [Google Scholar]
51.Sonnenburg JL, Chen CT, Gordon JI. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 2006;4:e413 doi: 10.1371/journal.pbio.0040413. PMID:17132046. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:573–83. doi: 10.1016/j.bpg.2014.07.004. PMID:25194176. [DOI] [PMC free article] [PubMed] [Google Scholar]
53.Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005;29:625–51. doi: 10.1016/j.femsre.2004.09.003. PMID:16102595. [DOI] [PubMed] [Google Scholar]
54.Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, et al.. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10:167–77. doi: 10.1016/j.cmet.2009.08.001. PMID:19723493. [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Pols TW, Nomura M, Harach T, Lo Sasso G, Oosterveer MH, Thomas C, Rizzo G, Gioiello A, Adorini L, Pellicciari R, et al.. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011; 14:747–57. doi: 10.1016/j.cmet.2011.11.006. PMID:22152303. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Cox HM, Tough IR, Woolston AM, Zhang L, Nguyen AD, Sainsbury A, Herzog H. Peptide YY is critical for acylethanolamine receptor Gpr119-induced activation of gastrointestinal mucosal responses. Cell Metab. 2010;11:532–42. doi: 10.1016/j.cmet.2010.04.014. PMID:20519124. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M, Pappas TN, et al.. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R1269–1276. doi: 10.1152/ajpregu.00442.2002. PMID:12676748. [DOI] [PubMed] [Google Scholar]
58.Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39:509–21. doi: 10.1093/femsre/fuu010. PMID:25701044. [DOI] [PubMed] [Google Scholar]
59.Queipo-Ortuno MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F, Tinahones FJ. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One. 2013;8:e65465. doi: 10.1371/journal.pone.0065465. PMID:23724144. [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89:1751–9. doi: 10.3945/ajcn.2009.27465. PMID:19386741. [DOI] [PMC free article] [PubMed] [Google Scholar]
61.Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut. 1996;38:916–9, 1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
62.Vrieze A, Holleman F, Zoetendal EG, de Vos WM, Hoekstra JB, Nieuwdorp M. The environment within: how gut microbiota may influence metabolism and body composition. Diabetologia. 2010;53:606–13. doi: 10.1007/s00125-010-1662-7. PMID:20101384. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, et al.. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60. doi: 10.1038/nature11450. PMID:23023125. [DOI] [PubMed] [Google Scholar]
64.Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, Manchester JK, Hammer RE, Williams SC, Crowley J, Yanagisawa M, et al.. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc Natl Acad Sci USA. 2008;105:16767–72. doi: 10.1073/pnas.0808567105. PMID:18931303. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288:25088–97. doi: 10.1074/jbc.M113.452516. PMID:23836895. [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Gustafsson BE, Midtvedt T, Norman A. Isolated fecal microorganisms capable of 7-alpha-dehydroxylating bile acids. J Exp Med. 1966;123:413–32. doi: 10.1084/jem.123.2.413. PMID:5325994. [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Iguchi Y, Yamaguchi M, Sato H, Kihira K, Nishimaki-Mogami T, Une M. Bile alcohols function as the ligands of membrane-type bile acid-activated G protein-coupled receptor. J. Lipid Res. 2010;51:1432–41. doi: 10.1194/jlr.M004051. PMID:20023205. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, et al.. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature. 2006;439:484–9. doi: 10.1038/nature04330. PMID:16400329. [DOI] [PubMed] [Google Scholar]
69.Karlsson F, Tremaroli V, Nielsen J, Bäckhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes. 2013;62:3341–9. doi: 10.2337/db13-0844. PMID:24065795. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, et al.. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterol. 2012;134:913–6.e7. doi: 10.1053/j.gastro.2012.06.031. [DOI] [PubMed] [Google Scholar]
71.Gomes AC, Bueno AA, De Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13. doi: 10.1186/1475-2891-13-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
72.Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36. Regul Pept. 1994;51:151–9. doi: 10.1016/0167-0115(94)90204-6. PMID:8059011. [DOI] [PubMed] [Google Scholar]
73.Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. Inhibition of food intake in obese subjects by peptide YY3–36. N Engl J Med. 2003;349:941–8. doi: 10.1056/NEJMoa030204. PMID:12954742. [DOI] [PubMed] [Google Scholar]
74.Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, et al.. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58:1091–103. doi: 10.1136/gut.2008.165886. PMID:19240062. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Psichas A, Sleeth ML, Murphy KG, Brooks L, Bewick GA, Hanyaloglu AC, Ghatei MA, Bloom SR, Frost G. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J Obes. 2015;39:424–9. doi: 10.1038/ijo.2014.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
76.Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E, Berry D. Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations. Environ MicroBiol. 2017;19:95–105. doi: 10.1111/1462-2920.13463. PMID:27450202. [DOI] [PMC free article] [PubMed] [Google Scholar]
77.Bervoets L, Hoorenbeeck KV, Kortleven I, Noten CV, Hens N, Vael C, Goossens H, Desager KN, Vankerckhoven V. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathogens. 2013;5:10. doi: 10.1186/1757-4749-5-10. PMID:23631345. [DOI] [PMC free article] [PubMed] [Google Scholar]
78.Munukka E, Wiklund P, Pekkala S, Völgyi E, Xu L, Cheng S, Lyytikäinen A, Marjomäki V, Alen M, Vaahtovuo J, et al.. Women with and without metabolic disorder differ in their gut microbiota composition. Obesity. 2012;20:1082–7. doi: 10.1038/oby.2012.8. PMID:22293842. [DOI] [PubMed] [Google Scholar]
79.Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y, et al.. Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing. BMC Gastroenterol. 2015;15:100. doi: 10.1186/s12876-015-0330-2. PMID:26261039. [DOI] [PMC free article] [PubMed] [Google Scholar]
80.Kocełak P, Zak-Gołąb A, Zahorska-Markiewicz B, Aptekorz M, Zientara M, Martirosian G, Chudek J, Olszanecka-Glinianowicz M. Resting energy expenditure and gut microbiota in obese and normal weight subjects. Eur Rev Med Pharmacol Sci. 2013;17:2816–21. PMID:24174366. [PubMed] [Google Scholar]
81.Jumpertz R, Le DS, Turnbaugh PJ, Trinidad C, Bogardus C, Gordon JI, Krakoff J. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr. 2011;94:58–65. doi: 10.3945/ajcn.110.010132. PMID:21543530. [DOI] [PMC free article] [PubMed] [Google Scholar]
82.Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One. 2009;4(9):e7125. doi: 10.1371/journal.pone.0007125. PMID:19774074. [DOI] [PMC free article] [PubMed] [Google Scholar]
83.Million M, Thuny F, Angelakis E, Casalta JP, Giorgi R, Habib G, Raoult D. Lactobacillus reuteri and Escherichia coli in the human gut microbiota may predict weight gain associated with vancomycin treatment. Nutr Diabetes. 2013;3:e87. doi: 10.1038/nutd.2013.28. PMID:24018615. [DOI] [PMC free article] [PubMed] [Google Scholar]
84.Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight-women. Am J Clin Nutr. 2008;88:894–9. doi: 10.1093/ajcn/88.4.894. PMID:18842773. [DOI] [PubMed] [Google Scholar]
85.Collado MC, Isolauri E, Laitinen K, Salminen S. Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy. Am J Clin Nutr. 2010;92:1023–30. doi: 10.3945/ajcn.2010.29877. PMID:20844065. [DOI] [PubMed] [Google Scholar]
86.Duncan SH, Lobley GE, Holtrop G, Ince J, Johnstone AM, Louis P, Flint HJ. Human colonic microbiota associated with diet, obesity and weight loss. Int J Obes. 2008;32:1720–4. doi: 10.1038/ijo.2008.155. [DOI] [PubMed] [Google Scholar]
87.Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran P, Crowell MD, Wing R, Rittmann BE, Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass. PNAS. 2009;106:2365–70. doi: 10.1073/pnas.0812600106. PMID:19164560. [DOI] [PMC free article] [PubMed] [Google Scholar]
88.Kong L, Tap J, Aron-Wisnewsky J, Pelloux V, Basdevant A, Bouillot J, Zucker J, Doré J, Clément K. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr. 2013;98:16–24. doi: 10.3945/ajcn.113.058743. PMID:23719559. [DOI] [PubMed] [Google Scholar]
89.Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Königsrainer A, Huson DH, Bischoff SC. Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption. BioMed Res Int. 2015;2015:1–12. doi: 10.1155/2015/806248. [DOI] [PMC free article] [PubMed] [Google Scholar]
90.Santacruz A, Collado MC, García-Valdés L, Segura MT, Martín-Lagos JA, Anjos T, Martí-Romero M, Lopez RM, Florido J, Campoy C, et al.. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br J Nutr. 2010;104:83–92. doi: 10.1017/S0007114510000176. PMID:20205964. [DOI] [PubMed] [Google Scholar]
91.Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008;87:534–8. doi: 10.1093/ajcn/87.3.534. PMID:18326589. [DOI] [PubMed] [Google Scholar]
92.Remely M, Tesar I, Hippe B, Gnauer S, Rust P, Haslberger AG. Gut microbiota composition correlates with changes in body fat content due to weight loss. Benef Microbes. 2015;6:431–9. doi: 10.3920/BM2014.0104. PMID:25609655. [DOI] [PubMed] [Google Scholar]
93.Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, et al.. Differential adaptation of human gut microbiota to bariatric surgery–induced weight loss links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57. doi: 10.2337/db10-0253. PMID:20876719. [DOI] [PMC free article] [PubMed] [Google Scholar]
94.Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring). 2010;18:190–5. doi: 10.1038/oby.2009.167. PMID:19498350. [DOI] [PubMed] [Google Scholar]
95.Begley M, Hill C, Gahan CG. Bile salt hydrolase activity in probiotics. Appl Environ MicroBiol. 2006;72:1729–38 doi: 10.1128/AEM.72.3.1729-1738.2006. PMID:16517616. [DOI] [PMC free article] [PubMed] [Google Scholar]
96.Yin Y-N, Yu Q-F, Fu N, Liu X-W, Lu F-G. Effects of four Bifidobacteria on obesity in high-fat diet induced rats. World J Gastroenterol. 2010;16:3394–401. doi: 10.3748/wjg.v16.i27.3394. PMID:20632441. [DOI] [PMC free article] [PubMed] [Google Scholar]
97.Basseri RJ, Basseri B, Pimentel M, Chong K, Youdim A, Low K, Hwang L, Soffer E, Chang C, Mathur R. Intestinal methane production in obese individuals is associated with a higher body mass index. Gastroenterol Hepatol. 2012;8:22–8. [PMC free article] [PubMed] [Google Scholar]
98.Wesolowska-Andersen A, Bahl MI, Carvalho V, Kristiansen K, Sicheritz-Pontén T, Gupta R, Licht TR. Choice of bacterial DNA extraction method from fecal material influences community structure as evaluated by metagenomic analysis. Microbiome. 2014;2:1–11. doi: 10.1186/2049-2618-2-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
99.Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2012;28:539–43. doi: 10.1016/j.nut.2011.08.013. PMID:22129852. [DOI] [PubMed] [Google Scholar]
100.Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur J Clin Nutr. 2010;64:636–43. doi: 10.1038/ejcn.2010.19. PMID:20216555. [DOI] [PubMed] [Google Scholar]
101.Gomes AC, de Sousa RG, Botelho PB, Gomes TL, Prada PO, Mota JF. The additional effects of a probiotic mix on abdominal adiposity and antioxidant status: a double-blind, randomized trial. Obesity. 2017;25:30–38. doi: 10.1002/oby.21671. PMID:28008750. [DOI] [PubMed] [Google Scholar]
102.Zhang Y, Wang L, Zhang J, Li Y, He Q, Li H, Guo X, Guo J, Zhang H. Probiotic Lactobacillus casei Zhang ameliorates high-fructose-induced impaired glucose tolerance in hyperinsulinemia rats. Eur J Nutr. 2014;53:221–32. doi: 10.1007/s00394-013-0519-5. PMID:23797890. [DOI] [PubMed] [Google Scholar]
103.Mai V, McCrary QM, Sinha R, Glei M. Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: an observational study in African American and Caucasian American volunteers. Nutr J. 2009;8:49. doi: 10.1186/1475-2891-8-49. PMID:19845958. [DOI] [PMC free article] [PubMed] [Google Scholar]
104.Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM, et al.. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity. 2009;17:1906–15. doi: 10.1038/oby.2009.112. PMID:19390523. [DOI] [PubMed] [Google Scholar]
105.Gauffin Cano P, Santacruz A, Moya Á, Sanz Y. Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysfunction in mice with high-fat-diet induced obesity. PLoS One. 2012;7:e41079. doi: 10.1371/journal.pone.0041079. PMID:22844426. [DOI] [PMC free article] [PubMed] [Google Scholar]
106.Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J Immunol. 2004;172:1118–24 doi: 10.4049/jimmunol.172.2.1118. PMID:14707086. [DOI] [PubMed] [Google Scholar]
107.Ochoa-Reparaz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, Kasper LH. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3:487–95. doi: 10.1038/mi.2010.29. PMID:20531465. [DOI] [PubMed] [Google Scholar]
108.Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal J, Garcia P, Cai J, Hippe H, Farrow JA. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol. 1994;44:812–26. doi: 10.1099/00207713-44-4-812. PMID:7981107. [DOI] [PubMed] [Google Scholar]
109.De Graaf AA, Venema K. Gaining insight into microbial physiology in the large intestine: a special role for stable isotopes. Adv Microb Physiol. 2008;53:73–168. PMID:17707144. [DOI] [PubMed] [Google Scholar]
110.Casas IA, Dobrogosz WJ. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis. 2000;12:247–85. doi: 10.1080/08910600050216246-1. [DOI] [Google Scholar]
111.Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, Paek KS, Lee Y, Park JH. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006;1761:736–44. doi: 10.1016/j.bbalip.2006.05.007. PMID:16807088. [DOI] [PubMed] [Google Scholar]
112.Le TK, Hosaka T, Le TT, Nguyen TG, Tran QB, Le TH, Pham XD. Oral administration of Bifidobacterium spp. improves insulin resistance, induces adiponectin, and prevents inflammatory adipokine expressions. Biomed Res. 2014;35:303–10. doi: 10.2220/biomedres.35.303. PMID:25355437. [DOI] [PubMed] [Google Scholar]
113.Chen J, Wang R, Li XF, Wang RL. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr. 2012;107:1429–34. doi: 10.1017/S0007114511004491. PMID:21914236. [DOI] [PubMed] [Google Scholar]
114.Fukuda S, Furuya H, Suzuki Y, Asanuma N, Hino T. A new strain of Butyrivibrio fibrisolvens that has high ability to isomerize linoleic acid to conjugated linoleic acid. J Gen Appl MicroBiol. 2005;51:105–13 doi: 10.2323/jgam.51.105. PMID:15942871. [DOI] [PubMed] [Google Scholar]
115.Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8:42. doi: 10.1186/s13073-016-0303-2. PMID:27098727. [DOI] [PMC free article] [PubMed] [Google Scholar]
116.Flint HJ, Duncan SH, Scott KP, Louis P. Interactions and competition within the microbial community of the human colon: links between diet and health. Environ MicroBiol. 2007;9:1101–11. doi: 10.1111/j.1462-2920.2007.01281.x. PMID:17472627. [DOI] [PubMed] [Google Scholar]

PERMALINK

The human gut microbiota: Metabolism and perspective in obesity

Aline Corado Gomes

Christian Hoffmann

João Felipe Mota

ABSTRACT

Introduction

Methods

Physiology of the gut microbiota

Function of the gut microbiota on the development of lymphoid structures

Function of the gut microbiota on the immune system

Function of the gut microbiota on nutrient metabolism and lipid metabolism

Short chain fatty acids

Lipid metabolism

Function of the gut microbiota on the hormones involved in food intake

The human gut microbiota composition in obesity

Phyla changes after weight loss

Table 1.

Obesity related genus changes

Gut microbiota and obesity: future perspectives

Table 2.

Conclusions

Figure 1.

List of Abbreviations

Disclosure of potential conflicts of interest

Acknowledgments

Authors' contributions

References

ACTIONS

PERMALINK

RESOURCES

Cite

Add to Collections

PERMALINK

The human gut microbiota: Metabolism and perspective in obesity

Aline Corado Gomes

Christian Hoffmann

João Felipe Mota

ABSTRACT

Introduction

Methods

Physiology of the gut microbiota

Function of the gut microbiota on the development of lymphoid structures

Function of the gut microbiota on the immune system

Function of the gut microbiota on nutrient metabolism and lipid metabolism

Short chain fatty acids

Lipid metabolism

Function of the gut microbiota on the hormones involved in food intake

The human gut microbiota composition in obesity

Phyla changes after weight loss

Table 1.

Obesity related genus changes

Gut microbiota and obesity: future perspectives

Table 2.

Conclusions

Figure 1.

List of Abbreviations

Disclosure of potential conflicts of interest

Acknowledgments

Authors' contributions

References

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases